BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37951158)

  • 1. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review.
    Taliento C; Restaino S; Scutiero G; Arcieri M; Bernardi G; Martinello R; Driul L; Perrone AM; Fagotti A; Scambia G; Greco P; Vizzielli G
    Eur J Surg Oncol; 2023 Dec; 49(12):107250. PubMed ID: 37951158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.
    Tempfer CB; Celik I; Solass W; Buerkle B; Pabst UG; Zieren J; Strumberg D; Reymond MA
    Gynecol Oncol; 2014 Feb; 132(2):307-11. PubMed ID: 24275155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis.
    Tempfer CB; Hilal Z; Dogan A; Petersen M; Rezniczek GA
    Eur J Surg Oncol; 2018 Jul; 44(7):1112-1117. PubMed ID: 29753612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.
    Nadiradze G; Giger-Pabst U; Zieren J; Strumberg D; Solass W; Reymond MA
    J Gastrointest Surg; 2016 Feb; 20(2):367-73. PubMed ID: 26511950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
    Robella M; Vaira M; De Simone M
    World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center.
    Ceribelli C; Debs T; Chevallier A; Piche MA; Bereder JM
    Surg Endosc; 2020 Jun; 34(6):2803-2806. PubMed ID: 32166545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis.
    Di Giorgio A; Schena CA; El Halabieh MA; Abatini C; Vita E; Strippoli A; Inzani F; Rodolfino E; Romanò B; Pacelli F; Rotolo S
    Surg Oncol; 2020 Sep; 34():270-275. PubMed ID: 32891341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer.
    Alyami M; Bonnot PE; Mercier F; Laplace N; Villeneuve L; Passot G; Bakrin N; Kepenekian V; Glehen O
    Eur J Surg Oncol; 2021 Jan; 47(1):123-127. PubMed ID: 32561204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Alyami M; Mercier F; Siebert M; Bonnot PE; Laplace N; Villeneuve L; Passot G; Glehen O; Bakrin N; Kepenekian V
    Eur J Surg Oncol; 2021 Jan; 47(1):128-133. PubMed ID: 31253545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
    Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
    Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study.
    Nowacki M; Alyami M; Villeneuve L; Mercier F; Hubner M; Willaert W; Ceelen W; Reymond M; Pezet D; Arvieux C; Khomyakov V; Lay L; Gianni S; Zegarski W; Bakrin N; Glehen O
    Eur J Surg Oncol; 2018 Jul; 44(7):991-996. PubMed ID: 29526367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
    Larbre V; Alyami M; Mercier F; Vantard N; Bonnefoy I; Opsomer MA; Villeneuve L; Bakrin N; Rioufol C; Glehen O; Kepenekian V
    Anticancer Res; 2018 Dec; 38(12):6869-6875. PubMed ID: 30504403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial.
    Somashekhar SP; Ashwin KR; Rauthan A; Rohit KC
    Pleura Peritoneum; 2019 Mar; 4(1):20180111. PubMed ID: 31198851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer.
    Tempfer C; Giger-Pabst U; Hilal Z; Dogan A; Rezniczek GA
    Arch Gynecol Obstet; 2018 Aug; 298(2):243-257. PubMed ID: 29869089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological Outcomes After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Peritoneal Carcinomatosis.
    Tidadini F; Abba J; Quesada JL; Trilling B; Bonne A; Foote A; Faucheron JL; Arvieux C
    J Gastrointest Cancer; 2023 Jun; 54(2):632-641. PubMed ID: 35778645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study.
    Struller F; Horvath P; Solass W; Weinreich FJ; Strumberg D; Kokkalis MK; Fischer I; Meisner C; Königsrainer A; Reymond MA
    Ther Adv Med Oncol; 2019; 11():1758835919846402. PubMed ID: 31205501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
    Tempfer CB; Giger-Pabst U; Seebacher V; Petersen M; Dogan A; Rezniczek GA
    Gynecol Oncol; 2018 Jul; 150(1):23-30. PubMed ID: 29743140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal malignancy: initial experience of the first program in the Baltic countries.
    Račkauskas R; Baušys A; Lukšta M; Jurgaitis J; Paškonis M; Strupas K
    World J Surg Oncol; 2021 Aug; 19(1):236. PubMed ID: 34376191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
    Odendahl K; Solass W; Demtröder C; Giger-Pabst U; Zieren J; Tempfer C; Reymond MA
    Eur J Surg Oncol; 2015 Oct; 41(10):1379-85. PubMed ID: 26138283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report.
    Siebert M; Alyami M; Mercier F; Gallice C; Villeneuve L; Bérard F; Glehen O; Bakrin N; Kepenekian V
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):425-430. PubMed ID: 30511218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.